A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate

Trial Profile

A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2016 Primary endpoint (Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Score Over Time Using the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition for Diagnosis) has been met according to the results published in the Journal of Clinical Psychiatry.
    • 02 Aug 2016 Results published in the Journal of Clinical Psychiatry
    • 21 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top